EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3989	((548/362.1,503,509) or (546/307, 312) or (514/403,415,352)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/09/30 17:01
L2	1448993	"2005".py.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/30 17:01
L3	145	1 and 2	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/09/30 17:01







My NCBI
[Sign In] [Register]

All Databases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	РМС	Journals	Books
Search PubMed		for #5 and #	111			Pre	view	o Clear	
	Limits	Preview/Inde	√ History  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓	ો Clipboard	Details				
About Entrez Text Version	<ul><li>To cor</li><li>Search</li></ul>	History will be mbine searches numbers may	use # befo not be con	re search nu tinuous; all	ımber, e.g., #2				
	• Click	on query # to a	dd to strate	gy					
Entrez PubMed Overview	Search		M	ost Recent	Queries			Time	Result
Help   FAQ Tutorial	<u>#15</u> \$	Search #5 and	#11					14:18:03	<u>13</u>
New/Noteworthy	<u>#14</u> :	Search #5 and	#10					14:17:58	<u>18</u>
E-Utilities	<u>#13</u> :	Search #5 and	#9					14:17:52	<u>0</u>
PubMed Services	<u>#12</u> :	Search #5 and	#8					14:17:44	<u>20</u>
Journals Database MeSH Database	<u>#11</u> \$	Search hyperli	poproteine	emia				14:17:24	<u>9566</u>
Single Citation Matcher Batch Citation Matcher	<u>#10</u> \$	Search hypercl	olesterole	mia				14:17:10	<u>24895</u>
Clinical Queries	<u>#9</u> :	Search pancre:	atitis					14:16:58	<u>38706</u>
Special Queries LinkOut	<u>#8</u> :	Search atheros	clerosis or	arterioscle	erosis			14:16:49	100498
My NCBI (Cubby)	<u>#5</u> \$	Search #1 and	#2 and #3	and #4				11:11:52	<u>57</u>
0.1.10	<u>#4</u> :	Search abnorn	ally high					11:11:32	<u>5219</u>
Related Resources Order Documents	<u>#3</u> \$	Search blood						11:11:24	<u>2477868</u>
NLM Mobile	<u>#2</u> :	Search choleste	erol					11:11:12	<u>148244</u>
NLM Catalog NLM Gateway TOXNET	<u>#1</u> S	Search low den	sity lipopi	otein				11:11:02	<u>41416</u>

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Sep 27 2005 04:32:41

Consumer Health Clinical Alerts

ClinicalTrials.gov PubMed Central Clear History

## HOME | ABOUT MERCK | PRODUCTS | NEWSROOM | INVESTOR INFORMATION | CAREERS | RESEARCH | LICENSING | THE MERCK MANUALS

SECTION

Disorders of Nutrition and Metabolism

CHAPTER

Cholesterol Disorders

**TOPICS** 

Introduction · Hyperlipoproteinemia · Hypolipoproteinemia

These search terms have been highlighted cholesterol levels in blood

## Introduction

Search The Second Home Edition, Search

Index

Online Version

Α	В	С	D	E	F	G	Н	ı
J	K	L	М	N	0	Р	Q	R
S	Т	U	٧	w	Х	Υ	Z	

Sections

Accidents and Injuries

**Blood Disorders** 

Bone, Joint, and Muscle Disorders

Brain, Spinal Cord, and Nerve Disorders

Cancer

Children's Health Issues

Digestive Disorders

Disorders of Nutrition and Metabolism

Drugs

Ear, Nose, and Throat Disorders

Eye Disorders

**Fundamentals** 

Heart and Blood Vesset Disorders

Hormonal Disorders

Immune Disorders

Infections

Kidney and Urinary Tract Disorders

Liver and Gallbladder Disorders

Lung and Airway Disorders

Men's Health Issues

Cholesterol and triglycerides are important fats (lipids) in the blood. Cholesterol is an essential component of cell membranes, brain and nerve cells, and bile, which helps the body absorb fats and fat-soluble vitamins. The body uses cholesterol to make vitamin D and various hormones, such as estrogen, testosterone, and cortisol. The body can produce all the cholesterol that it needs, but it also obtains cholesterol from food. Triglycerides, which are contained in fat cells, can be broken down, then used to provide energy for the body's metabolic processes, including growth. Triglycerides are produced in the intestine and liver from smaller fats called fatty acids. Some types of fatty acids are made by the body, but others must be obtained from food (see Overview of Nutrition: Fats).

Buy The Book

**Print This Topic** 

**Email This Topic** 

## **Pronunciations**

atherosclerosis

chylomicrons

hypolipoproteinemia

lipoproteins

pancreatitis

Fats, such as cholesterol and triglycerides, cannot circulate freely in the blood, because blood is mostly water. To be able to circulate in blood, cholesterol and triglycerides are packaged with proteins and other substances to form particles called lipoproteins.

There are different types of lipoproteins. Each type has a different purpose and is broken down and excreted in a slightly different way. Lipoproteins include chylomicrons, very low density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). Cholesterol transported by LDL is called LDL cholesterol, and cholesterol transported by HDL is called HDL cholesterol.

The body can regulate lipoprotein levels (and therefore lipid levels) by increasing or decreasing the production rate of lipoproteins. The body can also regulate how quickly lipoproteins enter and are removed from the bloodstream.

Levels of cholesterol and triglycerides vary considerably from day to day. From one measurement to the next, cholesterol levels can vary by about 10%, and triglyceride levels can vary by up to 25%.

Lipid levels may become abnormal because of changes that occur with aging, various disorders (including some hereditary ones), use of certain drugs, or lifestyle (consuming a high-fat diet, being physically inactive, or being overweight).

Abnormal levels of lipids (especially cholesterol) can lead to long-term problems, such

Mental Health Disorders
Mouth and Dental Disorders
Skin Disorders
Special Subjects
Women's Health Issues
Resources
Anatomical Drawings
Multimedia
Pronunciations
Weights and Measures
Common Medical Tests
Drug Names: Generic and Trade
Resources for Help and Information
About The Second Home Edition, Online Version

as atherosclerosis. Generally, a high total cholesterol level (which includes LDL, HDL, and VLDL cholesterol) or a high level of LDL (the "bad") cholesterol increases the risk of atherosclerosis and thus the risk of heart attack and stroke. However, not all types of cholesterol increase this risk. A high level of HDL (the "good") cholesterol may decrease risk, and conversely, a low level of HDL cholesterol increases risk. The effect of triglyceride levels on the risk of heart attack is less clear-cut. But very high levels of triglycerides (higher than 500 milligrams per deciliter of blood, or mg/dL) can increase the risk of pancreatitis. For people older than 20, levels of total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol after fasting should be measured at least once every 5 years. Collectively, these measurements are called the fasting lipoprotein profile.

Lipoproteins: Lipid Carriers								
Туре	Formation	Lipid Content	Function					
Chylomicrons	Formed from fats in food processed by the intestine	Mostly triglycerides	To transport digested fats (as triglycerides) to muscle and fat cells					
Very low density lipoprotein	Formed in the liver	More than <sup>1</sup> / <sub>2</sub> triglycerides	To transport triglycerides from the					
		About 1/4 cholesterol	liver to fat cells					
Low-density lipoprotein	Formed from VLDL after it delivers	More than <sup>1</sup> / <sub>2</sub> cholesterol	To transport cholesterol to various					
	triglycerides to fat cells	Less than <sup>1</sup> / <sub>10</sub> triglycerides	cells					
High-density	Formed in the liver	About 1/4 cholesterol	To remove					
lipoprotein	and small intestine	About <sup>1</sup> / <sub>20</sub> triglycerides	cholesterol from tissues in the body and transport it to the liver					

Back to Top

Next: Hyperlipoproteinemia

Animation Audio Illustrations Photographs Pronunciations Sidebar Tables Videos


SITE MAP | PRIVACY POLICY | TERMS OF USE | COPYRIGHT @ 1995-2005 MERCK & CO., INC.





□1: Stroke. 1993 Aug;24(8):1154-61.





Related Articles, Links

A CUI					of Medi	cine May	toidi. II	ij [ixegister]
All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM PMC	Journals	Books
Search PubMed		for				Go Clear		
	Limits	Preview/Inde	x Histor	y Clipboa	rd Details	` 5		
About Entrez		bstract		how 20 📳	Sort by	Send to		
Text Version	All: 1	Review: 0 🕱	J					

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia.

Rubba P, Faccenda F, Di Somma S, Gnasso A, Scarpato N, Iannuzzi A, Nappi G, Postiglione A, De Divitiis O, Mancini M.

Institute of Internal Medicine and Diseases of Metabolism, Medical School, University of Naples, Italy.

BACKGROUND AND PURPOSE: Low-density lipoprotein apheresis is currently used for the treatment of familial hypercholesterolemia, an inherited disorder of metabolism associated with premature development of cardiovascular disease. We wanted to evaluate cerebral blood flow velocity, cardiac output, and systemic vascular resistance in patients with familial hypercholesterolemia before and after low-density lipoprotein apheresis. METHODS: Ten patients (age range, 14 to 46 years; 4 males, 6 females) with familial hypercholesterolemia (8 homozygotes, 2 heterozygotes) and 10 healthy control subjects of comparable age and sex distribution participated in the study. Low-density lipoprotein apheresis by dextran sulfate was performed in 8 patients (7 homozygotes, 1 heterozygote). Six patients (4 homozygotes, 2 heterozygotes) underwent a procedure of extracorporeal erythrocyte filtration with the same extracorporeal volume as for low-density lipoprotein apheresis, but with the exclusion of the passage of plasma through the dextran sulfate column. Cerebral blood flow velocity (transcranial Doppler), cardiac output, and systemic vascular resistance (electric bioimpedance cardiography) were determined by noninvasive techniques before and 1 day and 7 days after low-density lipoprotein apheresis or extracorporeal erythrocyte filtration. Plasma and blood viscosities were measured at the same time. RESULTS: Before apheresis, mean and diastolic cerebral flow velocities were abnormally low in hypercholesterolemic patients (P < .01 and P < .02 vs healthy control subjects, respectively). After apheresis, low-density lipoprotein cholesterol was lowered by 40% to 60% from baseline, and cerebral blood flow velocities (mean, systolic, and diastolic velocities) were increased (P < .01). Cardiac output, systemic vascular resistance, and viscosity values were not significantly modified. Extracorporeal erythrocyte filtration (without passage of plasma through the dextran sulfate column) did not modify serum lipids, hemodynamic parameters, or viscosity values. CONCLUSIONS: Low-density lipoprotein apheresis produces potentially useful hemodynamic effects. They are not adequately explained by changes in blood viscosity alone and might reflect a restoration of endothelium-mediated vasodilation, which is inhibited by high concentrations of low-

## density lipoprotein.

PMID: 8342189 [PubMed - indexed for MEDLINE]

**********	<del>/-                                    </del>				···········	·····
Displa	Abstract	Sh	LO VV	y Send to		

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Sep 27 2005 04:32:41